Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letetresgene autoleucel in advanced NSCLC
NCT02588612Phase 1Completed
- Sponsor
- GSK
- Start
- Feb 2016
- Primary completion
- Aug 2020
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of letetresgene autoleucel in non-small cell lung cancer (NSCLC), sponsored by GSK. Primary endpoints: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 24 months, Number of Participants With Hematology Results by Maximum Grade Increase Post-Baseline up to 24 months and 3 more. Started Feb 2016; status: completed.
02
Drugs
letetresgene autoleucel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02588612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02588612.